| Platinum-based chemotherapy plus cetuximab in head and neck cancer JB Vermorken, R Mesia, F Rivera, E Remenar, A Kawecki, S Rottey, ... New England Journal of Medicine 359 (11), 1116-1127, 2008 | 2978 | 2008 |
| Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ... The Lancet 373 (9674), 1525-1531, 2009 | 1661 | 2009 |
| Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... New England Journal of Medicine 380 (12), 1116-1127, 2019 | 917 | 2019 |
| Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label … TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ... The Lancet 393 (10183), 1819-1830, 2019 | 820 | 2019 |
| Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung … MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ... J Clin Oncol 30 (17), 2055-2062, 2012 | 628 | 2012 |
| Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial JA Ajani, W Rodriguez, G Bodoky, V Moiseyenko, M Lichinitser, ... Journal of Clinical Oncology 28 (9), 1547-1553, 2010 | 612 | 2010 |
| Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label … L Paz-Ares, M Dvorkin, Y Chen, N Reinmuth, K Hotta, D Trukhin, ... The Lancet 394 (10212), 1929-1939, 2019 | 294 | 2019 |
| IMpower131: Primary PFS and safety analysis of a randomized phase III study of atezolizumab+ carboplatin+ paclitaxel or nab-paclitaxel vs carboplatin+ nab-paclitaxel as 1L … RM Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, DR Abreu, ... J Clin Oncol 36 (18_suppl), LBA9000, 2018 | 226 | 2018 |
| International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung … GV Scagliotti, I Vynnychenko, K Park, Y Ichinose, K Kubota, F Blackhall, ... | 189 | 2012 |
| First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data … U Gatzemeier, J Von Pawel, I Vynnychenko, P Zatloukal, F De Marinis, ... The lancet oncology 12 (1), 30-37, 2011 | 124 | 2011 |
| RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab In Combination with Chemotherapy for Second-Line … A Brufsky, I Bondarenko, V Smirnov, S Hurvitz, E Perez, O Ponomarova, ... Cancer Research 69 (24 Supplement), 42-42, 2009 | 107 | 2009 |
| Effect of a proposed trastuzumab biosimilar compared with trastuzumab on overall response rate in patients with ERBB2 (HER2)–positive metastatic breast cancer: a randomized … HS Rugo, A Barve, CF Waller, M Hernandez-Bronchud, J Herson, J Yuan, ... Jama 317 (1), 37-47, 2017 | 106 | 2017 |
| Multicenter phase III comparison of cisplatin/S-1 (CS) with cisplatin/5-FU (CF) as first-line therapy in patients with advanced gastric cancer (FLAGS): secondary and subset … JA Ajani, W Rodriquez, G Bodoky, V Moiseyenko, M Lichinitser, ... Journal of clinical oncology 27 (15_suppl), 4511-4511, 2009 | 83 | 2009 |
| Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study R Pirker, JR Pereira, A Szczesna, J Von Pawel, M Krzakowski, R Ramlau, ... Lung Cancer 77 (2), 376-382, 2012 | 59 | 2012 |
| Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for metastatic renal cell carcinoma (mRCC): Outcomes in the combined IMDC intermediate/poor … BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ... Journal of Clinical Oncology 37 (15_suppl), 4500-4500, 2019 | 56 | 2019 |
| FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18. 2 … SE Al-Batran, MH Schuler, Z Zvirbule, G Manikhas, F Lordick, A Rusyn, ... Journal of Clinical Oncology 34 (18_suppl), LBA4001-LBA4001, 2016 | 47 | 2016 |
| Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): results from a randomized phase III trial R Jotte, F Cappuzzo, I Vynnychenko, D Stroyakovskiy, ... Journal of Thoracic Oncology 15 (8), 1351-1360, 2020 | 45 | 2020 |
| Results of a randomized, phase III trial of nab-paclitaxel (nab-P) and carboplatin (C) compared with cremophor-based paclitaxel (P) and carboplatin as first-line therapy in … MA Socinski, IN Bondarenko, NA Karaseva, A Makhson, I Vynnichenko, ... Journal of Clinical Oncology 28 (18_suppl), LBA7511-LBA7511, 2010 | 31 | 2010 |
| An international, randomized, placebo-controlled, double-blind phase III study (MONET1) of motesanib plus carboplatin/paclitaxel (C/P) in patients with advanced nonsquamous non … G Scagliotti, I Vynnychenko, Y Ichinose, K Park, K Kubota, FH Blackhall, ... Journal of Clinical Oncology 29 (18_suppl), LBA7512-LBA7512, 2011 | 30 | 2011 |
| Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. ER Plimack, BI Rini, V Stus, R Gafanov, T Waddell, D Nosov, F Pouliot, ... Journal of Clinical Oncology 38 (15_suppl), 5001-5001, 2020 | 29 | 2020 |
